These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 16154026)

  • 1. [Spondylarthropathies and anti-TNFalpha drugs].
    Pavy S; Allanore Y; Kahan A
    Rev Med Interne; 2005 Sep; 26(9):717-24. PubMed ID: 16154026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumour necrosis factor (TNF)-alpha therapy in undifferentiated spondyloarthropathy.
    Schnarr S; Kuipers JG; Zeidler H
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S126-9. PubMed ID: 12463462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.
    De Keyser F; Baeten D; Van den Bosch F; Kruithof E; Verbruggen G; Mielants H; Veys E
    Drugs; 2004; 64(24):2793-811. PubMed ID: 15563249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
    Braun J
    Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.
    Kaltsonoudis E; Zikou AK; Voulgari PV; Konitsiotis S; Argyropoulou MI; Drosos AA
    Arthritis Res Ther; 2014 Jun; 16(3):R125. PubMed ID: 24938855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-TNFα therapy in ankylosing spondylitis: symptom control and structural damage modification].
    Andreu JL; Otón T; Sanz J
    Reumatol Clin; 2011; 7(1):51-5. PubMed ID: 21794779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.
    Sieper J; Braun J
    Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii58-61. PubMed ID: 11890656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
    Braun J; Brandt J; Listing J; Rudwaleit M; Sieper J
    Curr Opin Rheumatol; 2003 Jul; 15(4):394-407. PubMed ID: 12819466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
    Tse SM; Burgos-Vargas R; Laxer RM
    Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Seronegative spondylarthropathy: variable manifestations, common characteristics].
    van Rijthoven AW; Jacobs JW
    Ned Tijdschr Geneeskd; 2007 Jun; 151(25):1377-81. PubMed ID: 17668597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Rheumatoid arthritis: current status of therapy].
    El Bahri DM; Meddeb N; Sellami S
    Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
    Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
    J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
    Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
    Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNFalpha as therapeutic target: new drugs, more applications.
    Reimold AM
    Curr Drug Targets Inflamm Allergy; 2002 Dec; 1(4):377-92. PubMed ID: 14561184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
    Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies.
    Sulpice M; Deslandre CJ; Quartier P
    Joint Bone Spine; 2009 Jan; 76(1):24-7. PubMed ID: 19070529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.